The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, randomized phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT) for prostate cancer with relapse after initial hormonal therapy.
M. Takahashi
No relevant relationships to disclose
R. Kawabata
Employment or Leadership Position - Taiho Pharmaceutical
A. Kawano
No relevant relationships to disclose
Y. Murakami
No relevant relationships to disclose
Y. Sutou
No relevant relationships to disclose
T. Inai
No relevant relationships to disclose
S. Akazawa
No relevant relationships to disclose
T. Hamao
No relevant relationships to disclose
H. Hayashi
No relevant relationships to disclose
T. Fukawa
No relevant relationships to disclose
M. Takemura
No relevant relationships to disclose
Y. Yamamoto
No relevant relationships to disclose
K. Yamaguchi
No relevant relationships to disclose
H. Nakatsuji
No relevant relationships to disclose
T. Kishimoto
No relevant relationships to disclose
H. Izaki
No relevant relationships to disclose
T. Fukumori
No relevant relationships to disclose
H. Kanayama
No relevant relationships to disclose